|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:approves
|
gptkb:1987
gptkb:FDA
|
|
gptkbp:atccode
|
J05 AF01
|
|
gptkbp:brand
|
gptkb:AZT
|
|
gptkbp:can_be_combined_with
|
gptkb:abacavir
gptkb:lamivudine
gptkb:tenofovir
|
|
gptkbp:casnumber
|
30516-87-1
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:chemical_formula
|
C10 H13 N5 O4 S
|
|
gptkbp:class
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
severe liver disease
bone marrow suppression
hypersensitivity to zidovudine
|
|
gptkbp:discontinued
|
some countries
|
|
gptkbp:formulation
|
gptkb:Software_Solutions
gptkb:tablet
|
|
gptkbp:historical_significance
|
first drug approved for HIV treatment
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Retrovir
|
|
gptkbp:ingredients
|
gptkb:zidovudine
|
|
gptkbp:interacts_with
|
gptkb:rifampin
gptkb:acetaminophen
probenecid
|
|
gptkbp:is_monitored_by
|
liver function tests
blood cell counts
|
|
gptkbp:legal_status
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibits reverse transcriptase
|
|
gptkbp:replaced_by
|
combination therapies
|
|
gptkbp:research_focus
|
long-term effects
drug resistance
combination therapy effectiveness
|
|
gptkbp:route_of_administration
|
oral
intravenous
|
|
gptkbp:side_effect
|
gptkb:muscular_dystrophy
gptkb:anemia
gptkb:lipodystrophy
fatigue
headache
nausea
insomnia
lactic acidosis
peripheral neuropathy
neutropenia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
treatment of HIV
|
|
gptkbp:weight
|
267.3 g/mol
|
|
gptkbp:bfsParent
|
gptkb:azidothymidine_(AZT)
gptkb:AZT
|
|
gptkbp:bfsLayer
|
5
|